Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.46 |
| ▸ | ALPI | P09923 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | XIAP | P98170 | 1/20 | 0.46 |
| ▸ | TPH1 | P17752 | 3/20 | 0.42 |
| ▸ | FNTA | P49354 | 1/20 | 0.42 |
| ▸ | FNTB | P49356 | 1/20 | 0.42 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.42 |
| ▸ | GRB2 | P62993 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspartic Acid SCHEMBL27954511 | 0.94 | PTPN1 (0.43) | PTPN1SLC7A5ITGB3ITGA2BPTGS1 | |
| Aspartic Acid SCHEMBL2473894 | 0.94 | PTPN1 (0.43) | PTPN1SLC7A5ITGB3ITGA2BPTGS1 | |
| Aspartic Acid SCHEMBL28937732 | 0.94 | PTPN1 (0.43) | PTPN1SLC7A5ITGB3ITGA2BPTGS1 | |
| Leucine SCHEMBL1724133 | 0.93 | PTPN1 (0.43) | PTPN1SLC7A5ITGB3ITGA2BPTGS1 | |
| SCHEMBL3495948 | 0.87 | ALPI (0.44) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL7559199 | 0.87 | ITGB3 (0.52) | ITGB3ITGA2BFNTAFNTBPGGT1B | |
| SCHEMBL7781980 | 0.83 | ATM (0.43) | TDP1 | |
| SCHEMBL7546444 | 0.83 | ATM (0.43) | TDP1 | |
| SCHEMBL10614969 | 0.83 | FNTA (0.43) | FNTAFNTBPGGT1BKMT2A | |
| SCHEMBL6046921 | 0.82 | SLC7A5 (0.51) | PTPN1SLC7A5ITGB3ITGA2BPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200353088-A1 | PEPTIDE CONJUGATE CGRP RECEPTOR ANTAGONISTS AND METHODS OF PREPARATION AND USES THEREOF | AUCKLAND UNISERVICES LIMITED (NZ) | 2020-11-12 | — | — | US | claimed |
| EP-3707157-A1 | PEPTIDE CONJUGATE CGRP RECEPTOR ANTAGONISTS AND METHODS OF PREPARATION AND USES THEREOF | Auckland Uniservices Limited (NZ) | 2020-09-16 | — | — | EP | claimed |
| CN-111479823-A | Peptide conjugate CGRP receptor antagonist and preparation method and application thereof | 奥克兰联合服务有限公司 | 2020-07-31 | — | — | CN | claimed |
| US-7927864-B2 | Methods, kits, and compositions for detecting enzyme activity | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2011-04-19 | — | — | US | claimed |
| US-20090148851-A1 | Methods, kits, and compositions for detecting enzyme activity | OWEN JOHN | 2009-06-11 | — | — | US | claimed |
| US-7468258-B2 | Self-quenching homofluorophore compositions for detecting enzyme activity | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2008-12-23 | — | — | US | claimed |
| US-20070212696-A1 | Self-quenching homofluorophore compositions for detecting enzyme activity | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2007-09-13 | — | — | US | claimed |
| US-20200353088-A1 | PEPTIDE CONJUGATE CGRP RECEPTOR ANTAGONISTS AND METHODS OF PREPARATION AND USES THEREOF | AUCKLAND UNISERVICES LIMITED (NZ) | 2020-11-12 | — | — | US | disclosed |
| EP-3707157-A1 | PEPTIDE CONJUGATE CGRP RECEPTOR ANTAGONISTS AND METHODS OF PREPARATION AND USES THEREOF | Auckland Uniservices Limited (NZ) | 2020-09-16 | — | — | EP | disclosed |
| CN-111479823-A | Peptide conjugate CGRP receptor antagonist and preparation method and application thereof | 奥克兰联合服务有限公司 | 2020-07-31 | — | — | CN | disclosed |
| CN-103266133-B | The construction method of stably express clinic lamivudine drug resistance hepatitis B virus cell strain | 河南省医药科学研究院 | 2016-07-06 | — | — | CN | disclosed |
| US-8663912-B2 | Fluorogenic substrate for ADAMTS13 | WASHINGTON UNIVERSITY (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130023004-A1 | FLUOROGENIC SUBSTRATE FOR ADAMTS13 | WASHINGTON UNIVERSITY (US) | 2013-01-24 | — | — | US | disclosed |
| US-20070212696-A1 | Self-quenching homofluorophore compositions for detecting enzyme activity | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2007-09-13 | — | — | US | disclosed |
| CN-1599617-A | Pharmaceutical composition having prophylactic effects on lamivudine-related disease relapse and drug resistance and methods of using the same | WU TZU SHENG (CN) | 2005-03-23 | — | — | CN | disclosed |
| WO-2005012573-A1 | MICROARRAY COMPRISING PROBES FOR DRUG-RESISTANT HEPATITIS B VIRUS DETECTION, QUALITY CONTROL AND NEGATIVE CONTROL, AND METHOD FOR DETECTING DRUG-RESISTANT HEPATITIS B VIRUS USING THE SAME | KIM CHEOL-MIN (KR) | 2005-02-10 | — | — | WO | disclosed |
| EP-1144693-A3 | DETECTION OF ANTI-HEPATITIS B DRUG RESISTANCE | INNOGENETICS N.V. (BE) | 2001-11-28 | — | — | EP | disclosed |
| WO-2001088175-A1 | PROCESS FOR THE CONTINUOUS PRODUCTION OF DIPEPTIDE CRYSTALS IN A MEMBRANE AND HYDRO-CYCLONE REACTOR USING A PEPTIDASE | INSTITUTO SUPERIOR TÉCNICO (PT) | 2001-11-22 | — | — | WO | disclosed |
| EP-1144693-A2 | DETECTION OF ANTI-HEPATITIS B DRUG RESISTANCE | INNOGENETICS N.V. (BE) | 2001-10-17 | — | — | EP | disclosed |
| WO-2001004358-A2 | DETECTION OF ANTI-HEPATITIS B DRUG RESISTANCE | INNOGENETICS N.V. (BE) | 2001-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200353088-A1 | PEPTIDE CONJUGATE CGRP RECEPTOR ANTAGONISTS AND METHODS OF PREPARATION AND USES THEREOF | CALCRL, CALCR, GRPR | PTPN1 4160/4885SLC7A5 1069/4885ITGB3 1507/4885 |
| US-20130023004-A1 | FLUOROGENIC SUBSTRATE FOR ADAMTS13 | HM13, ADAMTS13, ADAMTS12 | PTPN1 2173/4885SLC7A5 1460/4885ITGB3 4454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.